Day: May 27, 2025

Issuer: Zelluna ASAISIN: NO0013524942Date of event triggering the notification: 27 May 2025Threshold crossed: 5% In accordance with the Norwegian Securities Trading Act Section 4-3, Gjelsten Holding AS (“Gjelsten”) hereby notifies that its ownership interest in Zelluna ASA (“Zelluna”) has fallen below the 5% threshold. Following a share capital increase in Zelluna through a private placement registered in VPS on 27 May 2025, Gjelsten’s ownership has changed as follows:Previous shareholding: 5.02% of the share capital New shareholding: 4.96% of the share capital Total number of shares held: 1,014,972 sharesThe reduction in ownership is due to dilution as a result of the private placement. Gjelsten has not sold any shares. This notification is submitted pursuant to Section 4-3 of the Norwegian Securities Trading...

Oslo, 27 May 2025: Zelluna ASA (the “Company”) refers to the announcement on 24 May 2025 regarding a resolution by the Company’s Board of Directors to issue 227,096 new shares in the Company against set-off of an option exercise fee. The share capital increase related to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises, and the Company’s new registered share capital is NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1. For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASA Email: hans.eid@zelluna.comPhone: +47 482 48632 About Zelluna ASAZelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global...

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the publication of a Japanese divisional patent. The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide (PEA) that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy, with potential for safer and more effective treatment for millions worldwide. “This patent represents a significant innovation in pain management, that potentially could offer a safer alternative for patients of all ages for using this very common...

Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares (“Shares”) of its common stock (“Common Stock”) or, in lieu thereof, to certain investors, pre-funded warrants (“Pre-Funded Warrants”) to purchase 6,963,556 shares of Common Stock,...

Company expected to join the index following FTSE Russell’s annual reconstitution on June 27, 2025 NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that it has been named a preliminary addition to the Russell 3000 Index, following the release of FTSE Russell’s list of 2025 index additions. Final inclusion is expected to take effect after the U.S. market opens on June 30, 2025, as part of the Russell indexes’ annual reconstitution, effective after market close on June 27, 2025. Membership in the Russell 3000 Index also results in automatic inclusion in the small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. Nexxen’s inclusion...

TORONTO, May 27, 2025 (GLOBE NEWSWIRE) — (TSXV: ROX) (OTCPK: CSRNF) Canstar Resources Inc. is ramping up critical metals exploration in Newfoundland with the receipt of the initial $500,000 tranche of its previously announced $11.5M strategic exploration joint venture with VMS Mining Corporation (“VMSC”). The non-dilutive investment positions Canstar to aggressively pursue the discovery of new, high-grade polymetallic (copper-zinc-lead-gold-silver) mineralization at its Buchans and Mary March volcanogenic massive sulphide (“VMS”) projects, located in one of Canada’s most prolific historic mining camps. “We have made meaningful progress. We are fortunate to operate in Newfoundland, where the exploration-friendly permitting process underpins our ability to move quickly and decisively,” said Juan Carlos Giron Jr., President...

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Exail Technologies (Euronext Paris: EXA; OTCQX: EXALF), a world-leading player in the fields of maritime drone systems and navigation systems, has qualified to trade on the OTCQX® Best Market. Exail Technologies upgraded to OTCQX from the Pink® market and is the first European company active in the defense sector to join the OTCQX Market. Exail Technologies begins trading today on OTCQX under the symbol “EXALF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The company continues to be traded simultaneously on its home market, Euronext, as well as on the U.S. market, strengthening...

The Republic of Iceland has successfully repurchased, for cancellation, EUR 203.7 million in nominal value of its outstanding 0.625% Eurobonds due 2026 (ISIN: XS2182399274), representing over 40% of the original EUR 500 million issue. The buyback was executed at a price of 98.81%, equivalent to approximately ISK 29 billion. The tender offer was launched on Monday, 19 May 2025 and closed at 17:00 BST on Friday, 23 May 2025. This transaction is part of the Treasury’s ongoing liquidity and debt management strategy, aimed at reducing near-term refinancing risk and improving the maturity profile of the Government’s debt portfolio. The buyback was financed from proceeds of the new EUR 750 million Eurobond issued earlier last week.

Highlights and subsequent eventsGolar LNG Limited (“Golar” or “the Company”) reports Q1 2025 net income attributable to Golar of $8 million, Adjusted EBITDA1 of $41 million and Total Golar Cash1 of $678 million.Concluded the 20-year charter of FLNG Hilli for Southern Energy S.A. (“SESA”) in Argentina.Signed definitive agreements for a 20-year charter for the MKII FLNG to SESA. Combined with the FLNG Hilli charter, the project will be for 5.95 mtpa of nameplate capacity – one of the world’s largest FLNG development projects.FLNG Gimi in final stages of commissioning on the GTA field, Commercial Operations Date (“COD”) expected within Q2.MKII FLNG conversion vessel Fuji LNG arrived at the shipyard for conversion works, conversion project on schedule for Q4 2027 delivery.FLNG Hilli maintained market-leading...